Working in Concert to Improve PKU Treatment Options

Even with management, PKU can still affect your daily life.

Maintaining a strict lifelong diet can be difficult and frustrating. Spikes in phenylalanine (Phe) levels can lead to trouble concentrating, depression, and other problems. That’s why we’re working to create more options to help you better manage your PKU.

Synlogic is conducting a Phase 2 clinical research study to evaluate the effectiveness (changes in blood Phe), safety, and tolerability of a potential new treatment option for PKU. This is the third clinical study conducted by Synlogic to investigate this potential treatment.

A potential new type of oral treatment for PKU.

Enrolling study participants diagnosed with classic PKU, ages 18 years and older.

Study participants receive close care and monitoring.

Study participants receive the study drug and assessments at no cost.

Study participants have the option to participate either at a study clinic or at a remote location such as their home with a home health professional.

Compensation for participation, including travel and study-related activities, will also be available.

Interested in helping advance a potential new treatment option for PKU?

Just answer a few questions below, and we can get you on your way to participating.

What is your ZIP / post code?


 

How old are you?

 

By clicking Submit, you are giving us permission to use the information you provide to determine if you may be eligible to participate in this clinical research study. For more details about how your information is used and protected, please see our Privacy Policy.